Bristol-Myers Squibb Co BMY

Stock XNYS Rating as of Jun 12, 2026

$55.92 −0.32 (0.57%)

View Full Chart

As of Jun 16, 2026, 8:00:15 PM Delayed Price Post-Trading: $55.84 −0.07

Company Report

View Archive

Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat

Karen Andersen May 12, 2026

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is evident in the acquisition of Celgene, which netted the firm an excellent pipeline and a strong foothold in blood cancer. More recent acquisitions—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat.

Read Full Report

Price vs Fair Value

View History

BMY is trading at a 128% premium.

Price

$57.13

Jun 12, 2026

Fair Value

$37.00

Feb 5, 2026

Uncertainty

Clnkd

1-Star Price: $26.10
5-Star Price: $47.00
Economic Moat: Jjv
Capital Allocation: Nwrtbnqyw

Bulls Say, Bears Say

Bulls

Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories, given the high unmet medical need.

Bears

The acquisition of Celgene came shortly before the start of generic competition for that firm's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

News

View All

Articles & Videos

Trading Information

Previous Close Price: $56.24
Day Range: $55.45–56.62
52-Week Range: $42.52–62.89
Bid/Ask: $55.70 / $55.99
Shares Outstanding: 2.04B
Market Cap: $114.19B
Volume/Avg: 12M / 12M

Key Statistics

Price/Earnings (Normalized): 9.67
Price/Sales: 2.40
Dividend Yield (Trailing): 4.43%
Dividend Yield (Forward): 4.46%
Total Yield: 4.38%

Company Profile

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Sector: Healthcare
Industry: Drug Manufacturers - General
Stock Style Box: Large Value
Total Number of Employees: 32,500
Website: https://www.bms.com

Competitors

Valuation

Metric	BMY	LLY	AZN
Price/Earnings (Normalized)	9.67	38.51	19.54
Price/Book Value	5.81	32.45	5.81
Price/Sales	2.40	14.08	4.66
Price/Cash Flow	7.92	37.87	17.69

Price/Earnings

BMY

LLY

AZN

Financial Strength

Metric	BMY	LLY	AZN
Quick Ratio	1.18	0.72	0.70
Current Ratio	1.42	1.50	0.91
Interest Coverage	6.31	—	8.17

Quick Ratio

BMY

LLY

AZN

Profitability

Metric	BMY	LLY	AZN
Return on Assets (Normalized)	13.15%	24.73%	9.16%
Return on Equity (Normalized)	65.90%	114.33%	22.59%
Return on Invested Capital (Normalized)	19.89%	40.96%	14.71%

Return on Assets

BMY

LLY

AZN

Drug Manufacturers - General Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Eli Lilly and Co LLY	Bcfmfkrwc	Pltl	$1T
Johnson & Johnson JNJ	Vdvsqrss	Jwxy	$580B
AbbVie Inc ABBV	Ssdddjdv	Pwr	$402B
Roche Holding AG ADR RHHBY	Bbbljyymg	Sqh	$331B
Merck & Co Inc MRK	Wxdnjptw	Lbwy	$294B
Novartis AG ADR NVS	Hdqsykmrw	Gfrl	$293B
AstraZeneca PLC AZN	Glyqqxknmp	Qvqw	$280B
Novo Nordisk AS ADR NVO	Csxldtygz	Lqx	$197B
Amgen Inc AMGN	Hljfsqxvn	Lfz	$192B
Gilead Sciences Inc GILD	Ybwwcvmx	Zmgt	$156B

Bristol-Myers Squibb Co BMY

Company Report

Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat

Price vs Fair Value

Bulls Say, Bears Say

Bulls

Bears

News

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Early Detection in Brazil Is a Game Changer for Lung Cancer Care

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Bristol-Myers Squibb on Pace for Largest Percent Decrease Since July 2025 — Data Talk

Bristol Myers Gets Speedy FDA Review of Camzyos in Adolescents

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Articles & Videos

3 Stocks to Invest In to Rebalance Your Portfolio

The Best Healthcare Stocks to Buy

10 Best Blue-Chip Stocks to Buy for the Long Term

The Best Companies to Own: 2026 Edition

5 Stocks to Buy Before They’re Not Undervalued Anymore

Best Innovative Companies to Own: 2026 Edition

As Tech Struggles, Dividend Stocks Step Back Into the Limelight

Markets Brief: What’s Clipping Microsoft Stock, Pharma Earnings and Jobs Report on Deck

2 Top Blue-Chip Stocks to Buy and Hold in 2026

Trading Information

Key Statistics

Company Profile

Competitors

Valuation

Financial Strength

Profitability

Drug Manufacturers - General Industry Comparables

Sponsor Center

What We Do

Company

Get Help